High ACSS2 expression predicted a poor prognosis in patients with renal cell carcinoma and bladder cancer (21, 22), whereas low ACSS2 expression predicted a poor prognosis in gastric cancer and hepatocellular carcinoma (23, 24). Here, ACSS2 is linked to urinary bladder cancer.